- Home
- IBOC vs PCVX Comparison
IBOC vs PCVX Comparison
Compare IBOC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- PCVX
- Stock Information
- Founded
- IBOC 1966
- PCVX 2013
- Country
- IBOC United States
- PCVX United States
- Employees
- IBOC N/A
- PCVX N/A
- Industry
- IBOC Major Banks
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- IBOC Finance
- PCVX Health Care
- Exchange
- IBOC Nasdaq
- PCVX Nasdaq
- Market Cap
- IBOC 3.8B
- PCVX 4.4B
- IPO Year
- IBOC N/A
- PCVX 2020
- Fundamental
- Price
- IBOC $70.01
- PCVX $36.46
- Analyst Decision
- IBOC
- PCVX Strong Buy
- Analyst Count
- IBOC 0
- PCVX 10
- Target Price
- IBOC N/A
- PCVX $136.50
- AVG Volume (30 Days)
- IBOC 212.2K
- PCVX 1.5M
- Earning Date
- IBOC 08-04-2025
- PCVX 08-05-2025
- Dividend Yield
- IBOC 2.01%
- PCVX N/A
- EPS Growth
- IBOC 0.30
- PCVX N/A
- EPS
- IBOC 6.57
- PCVX N/A
- Revenue
- IBOC $803,860,000.00
- PCVX N/A
- Revenue This Year
- IBOC N/A
- PCVX N/A
- Revenue Next Year
- IBOC N/A
- PCVX N/A
- P/E Ratio
- IBOC $10.60
- PCVX N/A
- Revenue Growth
- IBOC 1.14
- PCVX N/A
- 52 Week Low
- IBOC $54.11
- PCVX $27.66
- 52 Week High
- IBOC $76.91
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- IBOC 60.76
- PCVX 56.97
- Support Level
- IBOC $69.02
- PCVX $35.25
- Resistance Level
- IBOC $70.79
- PCVX $37.95
- Average True Range (ATR)
- IBOC 1.50
- PCVX 1.58
- MACD
- IBOC -0.14
- PCVX 0.17
- Stochastic Oscillator
- IBOC 59.43
- PCVX 75.81
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.